speb/financial-data huggingface dataset:
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 6910000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 1197455499.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 1196180556.00
BIOCON.NS income_statement (annual, 2025-03-31) — Basic EPS: 8.46
BIOCON.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 2.88
BIOCON.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 9195000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 36115000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 36115000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -23433000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 6065000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 6065000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 6003000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 6003000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 32267000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 32267000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 49242000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 49242000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -829000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 12779000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 12779000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 19488000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 19488000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -3000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -2057000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Change In Payable: 5808000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 5482000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 9230000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 19731000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Common Stock: 6003000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 6003000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 216440000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 216440000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 104000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: 0.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 42954000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 42954000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 51980000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 14729000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Assets: 162862000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 162862000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 674000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 674000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Debt: 53501000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 53501000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 54175000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 54175000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 143338000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 143338000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 1916000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 1916000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Deferred Tax: 4572000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Depreciation: 10011000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 16870000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 16870000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 4363000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 10011000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 4363000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Derivative Product Liabilities: 14418000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 14418000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 1198201789.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 1200348432.00
BIOCON.NS income_statement (annual, 2025-03-31) — Diluted EPS: 8.46
BIOCON.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 2.87
BIOCON.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 10133000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 3445000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 5000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 5000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 28000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — EBIT: 27743000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — EBIT: 6992000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — EBITDA: 44613000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — EBITDA: 11355000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 312000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — End Cash Position: 29238000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Financial Assets: 1874000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets: 1874000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 560000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 560000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -18540000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 18101000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 18101000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 17179000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: 387000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of Business: 0.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 76000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 6221000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Goodwill: 167857000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 167857000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 270576000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 270576000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 55506000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 55506000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 204040000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 204040000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Gross Profit: 98542000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 28852000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 964000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 964000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Held To Maturity Securities: 0.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 0.00
BIOCON.NS income_statement (annual, 2025-03-31) — Interest Expense: 8877000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 2124000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 8877000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 2124000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Interest Income: 1087000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 1087000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -6342000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 1144000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Inventory: 49311000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 49311000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 393995000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 393995000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -2341000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 7470000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 7470000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 104000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 103428000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 4100000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 4100000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 5391000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 5391000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 124054000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 124054000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 129445000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 129445000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 96582000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -97699000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 0.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 0.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 2608000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 2608000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 116549000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 116549000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 60685000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 60685000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Minority Interests: -4161000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Minority Interests: -1149000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 18252000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 104000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Net Debt: 145288000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 145288000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -576000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income: 10133000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income: 3445000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 10133000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 3445000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 14294000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 4594000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 10133000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 3445000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 10133000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 3445000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 14294000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 14294000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 4594000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -2067000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Interest Income: -7887000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -2124000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 1665000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 5729000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -1117000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -7887000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -2124000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: -15814000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Net PPE: 136078000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 136078000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -21363000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 6846000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: -54136000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -54136000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 3366000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 3366000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 2577000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 2577000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3577000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3577000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 2692000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 2692000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 33596000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 11151000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Normalized Income: 1785867698.51
BIOCON.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 3252482333.61
BIOCON.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 40612000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Operating Income: 16259000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Operating Income: 6419000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Operating Revenue: 150522000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 43581000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 1198063078.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 1198063078.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 7474000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 7474000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 370000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 370000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 4249000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 4249000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 102719000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 102719000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 4299000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 4299000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -1305000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 4757000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 4757000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 5126000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 5126000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 11000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 369000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 16583000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 10918000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Payable: 9321000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 9321000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Properties: 4322000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 4322000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 964000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 964000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 16975000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 16975000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Other Special Charges: -11462000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Payables: 78851000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Payables: 78851000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 7474000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 7474000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Pretax Income: 18866000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 4868000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 260000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -2067000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -102417000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -21366000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 9679000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 9679000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 51980000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 14729000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 16870000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 4363000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 195000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 195000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -97699000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: 0.00
BIOCON.NS income_statement (annual, 2025-03-31) — Research And Development: 6341000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Research And Development: -370000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 28000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 28000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 189591000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 189591000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Sale Of Business: 18252000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 104082000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 3000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 6499000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 12720000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Share Issued: 1200600000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 1200600000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Short Term Debt Issuance: 6846000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Special Income Charges: 11432000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 204000000.00
BIOCON.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 1370000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 216440000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 216440000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: -54136000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -54136000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 2669867698.51
BIOCON.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 11482333.61
BIOCON.NS income_statement (annual, 2025-03-31) — Tax Provision: 4572000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 274000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.24
BIOCON.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.06
BIOCON.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -4596000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Assets: 587973000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 587973000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 340494000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 340494000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Debt: 183620000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 183620000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 277125000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 277125000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Total Expenses: 134263000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 37162000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 310848000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 310848000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 425111000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 425111000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 167510000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 167510000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 97000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 4038000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 4038000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 11017000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 204000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 11017000000.00
BIOCON.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 204000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 8970000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 8970000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 2536922.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 2536922.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Treasury Stock: 784000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 784000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Work In Process: 17232000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 17232000000.00
BIOCON.NS balance_sheet (annual, 2025-03-31) — Working Capital: 19524000000.00
BIOCON.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 19524000000.00
BIOCON.NS income_statement (annual, 2025-03-31) — Write Off: 30000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 22111000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 39101000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 1207692308.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 0.26
BIOCON.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 14051000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 4550000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 4550000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 1207692308.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.26
BIOCON.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — EBIT: 3736000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — EBITDA: 8286000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 25050000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 2767000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 2767000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -578000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 892000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 892000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -2767000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -2767000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 8286000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 314000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Operating Income: 2939000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 39101000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 797000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 9894000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 969000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 14051000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 4550000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Research And Development: -346000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 77000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.08
BIOCON.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 36162000000.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
BIOCON.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 23531000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 42625000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 69756000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 55192000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 9602000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 1280303030.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 0.66
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 6278000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 6685000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 42747000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 64692000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 6685000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 268036000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 46508000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 15470000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 187811000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 697000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 53377000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 54074000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 162542000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 2122000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 4730000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 4730000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Derivative Product Liabilities: 747000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 1300000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.65
BIOCON.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 845000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — EBIT: 4435000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — EBITDA: 9165000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Financial Assets: 924000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 174600000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 277865000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 141267000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 27155000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Hedging Assets Current: 404000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 2722000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 2722000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 57768000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 427113000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 9602000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 5581000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 105700000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 111281000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 2715000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 62516000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Minority Interests: -483000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 116330000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income: 845000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 845000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 1328000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 845000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 845000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 1328000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -2722000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -2722000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 141267000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -9829000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 2964000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 2532000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 9284000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 937254524.23
BIOCON.NS income_statement (quarterly, 2025-09-30) — Operating Income: 3624000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 42625000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 1335075994.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 9755000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 8415000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 261351000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 103265000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 3438000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 3302000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 930000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 10386000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 94759000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 21945000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Payables: 71813000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 1713000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 15470000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 4730000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Research And Development: -132000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 1336963635.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: -119000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 268036000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -9829000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -26745475.77
BIOCON.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 385000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.22
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 627598000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 373736000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 165355000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 330552000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 39001000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 297046000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 439787000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 134504000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 2057000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: -119000000.00
BIOCON.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -119000000.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 1887641.00
BIOCON.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 25269000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 25155000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 41730000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 1331481481.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 1.08
BIOCON.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 13393000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 5153000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 5153000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 1343925234.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.07
BIOCON.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 1438000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — EBIT: 1421000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — EBITDA: 6574000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 28337000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 2099000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 2099000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 1956000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income: 1438000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 1438000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -518000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 1438000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 1438000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -518000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -2099000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -2099000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 9508000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 3679610619.47
BIOCON.NS income_statement (quarterly, 2025-12-31) — Operating Income: 3182000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 41730000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 1173000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 11782000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Pretax Income: -678000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 13393000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 5153000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Research And Development: -531000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -2934000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -692389380.53
BIOCON.NS income_statement (quarterly, 2025-12-31) — Tax Provision: -160000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.24
BIOCON.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 38548000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -2934000000.00
BIOCON.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -2934000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — +Operating Expense: 93630000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 25781000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — +Total Revenue: 167799000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 44843000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 67721000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 67721000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 59868000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 59868000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -79899000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -79899000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 156892000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 156892000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -850000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -850000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Amortization: 8022000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 8022000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 13777000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 13777000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 1366199012.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 1593670886.00
BIOCON.NS income_statement (annual, 2026-03-31) — Basic EPS: 2.82
BIOCON.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 0.79
BIOCON.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 29238000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 40169000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 40169000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -19117000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 6094000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 6094000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 8105000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 8105000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 24160000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 24160000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 40426000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 40426000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -908000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 13111000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 13111000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 11049000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 11049000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -9178000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -6471000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Change In Payable: -1917000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 6244000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -11322000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -10117000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Common Stock: 8105000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 8105000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 340318000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 340318000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 86015000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -26000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 46833000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 46833000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 56948000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 13993000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Assets: 171798000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 171798000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 724000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 724000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Debt: 40784000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 40784000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 41508000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 41508000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 140692000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 140692000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 2555000000.00